Cure My Disease

Don't miss your cure!

 Log in / Sign up

Silence no more: gene therapy aims to cure deafness in kids

NCT ID NCT07288580

Recruiting now ⭐️ CURE ⭐️ Sponsor: Shanghai Euhearing Therapeutics Co., Ltd Source: ClinicalTrials.gov ↗

First seen Jan 03, 2026 · Last updated Jun 06, 2026 · Updated 28 times

Summary

This study tests a new gene therapy called EHT102 for children born with severe hearing loss caused by mutations in the OTOF gene. Up to 30 children will receive a single injection into the ear to deliver a working copy of the gene. The goal is to safely restore hearing to a level where they can hear sounds at normal conversational volume.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TREATMENT OF CONGENITAL HEARING LOSS SECONDARY TO BIALLELIC MUTATIONS OF THE OTOFERLIN GENE (OTOF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Eye & ENT Hospital of Fudan University

    RECRUITING

    Shanghai, Shanghai Municipality, 200032, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

The condition(s) this trial relates to.

autosomal recessive nonsyndromic hearing loss 9

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TREATMENT OF CONGENITAL HEARING LOSS SECONDARY TO BIALLELIC MUTATIONS OF THE OTOFERLIN GENE (OTOF)